Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Biochem Pharmacol
2020 Nov 01;181:114124. doi: 10.1016/j.bcp.2020.114124.
Show Gene links
Show Anatomy links
Critical residue properties for potency and selectivity of α-Conotoxin RgIA towards α9α10 nicotinic acetylcholine receptors.
Huynh PN
,
Harvey PJ
,
Gajewiak J
,
Craik DJ
,
Michael McIntosh J
.
???displayArticle.abstract???
The α9α10 nicotinic acetylcholine receptor (nAChR) has been characterized as an effective anti-pain target that functions through a non-opioid mechanism. However, as a pentameric ion channel comprised of two different subunits, the specific targeting of α9α10 nAChRs has proven challenging. Previously the 13-amino-acid peptide, RgIA, was shown to block α9α10 nAChRs with high potency and specificity. This peptide, characterized from the venom of the carnivorous marine snail, Conus regius, produced analgesia in several rodent models of chronic pain. Despite promising pre-clinical data in behavioral assays, the number of specific α9α10 nAChR antagonists remains small and the physiological mechanisms of analgesia remain cryptic. In this study, we implement amino-acid substitutions to definitively characterize the chemical properties of RgIA that contribute to its activity against α9α10 nAChRs. Using this mutational approach, we determined the vital role of biochemical side-chain properties and amino acids in the second loop that are amenable to substitutions to further engineer next-generation analogs for the blockade of α9α10 nAChRs.
Azam,
Molecular basis for the differential sensitivity of rat and human α9α10 nAChRs to α-conotoxin RgIA.
2012, Pubmed,
Xenbase
Azam,
Molecular basis for the differential sensitivity of rat and human α9α10 nAChRs to α-conotoxin RgIA.
2012,
Pubmed
,
Xenbase
Callaghan,
Analgesic alpha-conotoxins Vc1.1 and Rg1A inhibit N-type calcium channels in rat sensory neurons via GABAB receptor activation.
2008,
Pubmed
,
Xenbase
Callaghan,
Analgesic α-conotoxins Vc1.1 and RgIA inhibit N-type calcium channels in sensory neurons of α9 nicotinic receptor knockout mice.
2010,
Pubmed
Castro,
Cyclic analogues of α-conotoxin Vc1.1 inhibit colonic nociceptors and provide analgesia in a mouse model of chronic abdominal pain.
2018,
Pubmed
Christensen,
RgIA4 Potently Blocks Mouse α9α10 nAChRs and Provides Long Lasting Protection against Oxaliplatin-Induced Cold Allodynia.
2017,
Pubmed
,
Xenbase
Clark,
The engineering of an orally active conotoxin for the treatment of neuropathic pain.
2010,
Pubmed
Di Cesare Mannelli,
α-conotoxin RgIA protects against the development of nerve injury-induced chronic pain and prevents both neuronal and glial derangement.
2014,
Pubmed
Di Cesare Mannelli,
Involvement of α7 nAChR subtype in rat oxaliplatin-induced neuropathy: effects of selective activation.
2014,
Pubmed
Ellison,
Alpha-RgIA: a novel conotoxin that specifically and potently blocks the alpha9alpha10 nAChR.
2006,
Pubmed
,
Xenbase
Ellison,
Alpha-RgIA, a novel conotoxin that blocks the alpha9alpha10 nAChR: structure and identification of key receptor-binding residues.
2008,
Pubmed
Ellison,
Alpha-conotoxins ImI and ImII target distinct regions of the human alpha7 nicotinic acetylcholine receptor and distinguish human nicotinic receptor subtypes.
2004,
Pubmed
,
Xenbase
Ellison,
Alpha-conotoxins ImI and ImII. Similar alpha 7 nicotinic receptor antagonists act at different sites.
2003,
Pubmed
Hecker,
Phosphocholine-Modified Macromolecules and Canonical Nicotinic Agonists Inhibit ATP-Induced IL-1β Release.
2015,
Pubmed
Holtman,
The novel small molecule α9α10 nicotinic acetylcholine receptor antagonist ZZ-204G is analgesic.
2011,
Pubmed
,
Xenbase
Hone,
α9-containing nicotinic acetylcholine receptors and the modulation of pain.
2018,
Pubmed
Huynh,
Novel mechanism of voltage-gated N-type (Cav2.2) calcium channel inhibition revealed through α-conotoxin Vc1.1 activation of the GABA(B) receptor.
2015,
Pubmed
Le Novère,
Molecular evolution of the nicotinic acetylcholine receptor: an example of multigene family in excitable cells.
1995,
Pubmed
Lebedev,
Oligoarginine Peptides, a New Family of Nicotinic Acetylcholine Receptor Inhibitors.
2019,
Pubmed
,
Xenbase
Lewis,
Conus venom peptide pharmacology.
2012,
Pubmed
Li,
Anti-hypersensitive effect of intramuscular administration of αO-conotoxin GeXIVA[1,2] and GeXIVA[1,4] in rats of neuropathic pain.
2016,
Pubmed
Luo,
Cloning, synthesis, and characterization of αO-conotoxin GeXIVA, a potent α9α10 nicotinic acetylcholine receptor antagonist.
2015,
Pubmed
,
Xenbase
Pacini,
The α9α10 nicotinic receptor antagonist α-conotoxin RgIA prevents neuropathic pain induced by oxaliplatin treatment.
2016,
Pubmed
Peng,
Characterization of the human nicotinic acetylcholine receptor subunit alpha (alpha) 9 (CHRNA9) and alpha (alpha) 10 (CHRNA10) in lymphocytes.
2004,
Pubmed
Richter,
C-Reactive Protein Stimulates Nicotinic Acetylcholine Receptors to Control ATP-Mediated Monocytic Inflammasome Activation.
2018,
Pubmed
Richter,
Phosphocholine - an agonist of metabotropic but not of ionotropic functions of α9-containing nicotinic acetylcholine receptors.
2016,
Pubmed
,
Xenbase
Romero,
Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain.
2017,
Pubmed
Sadeghi,
Analgesic conopeptides targeting G protein-coupled receptors reduce excitability of sensory neurons.
2017,
Pubmed
Satkunanathan,
Alpha-conotoxin Vc1.1 alleviates neuropathic pain and accelerates functional recovery of injured neurones.
2005,
Pubmed
Sokalingam,
A study on the effect of surface lysine to arginine mutagenesis on protein stability and structure using green fluorescent protein.
2012,
Pubmed
Tsunoyama,
Evolution of nicotinic acetylcholine receptor subunits.
1998,
Pubmed
Ulloa,
The vagus nerve and the nicotinic anti-inflammatory pathway.
2005,
Pubmed
Vincler,
Molecular mechanism for analgesia involving specific antagonism of alpha9alpha10 nicotinic acetylcholine receptors.
2006,
Pubmed
Wang,
The α9α10 Nicotinic Acetylcholine Receptor Antagonist αO-Conotoxin GeXIVA[1,2] Alleviates and Reverses Chemotherapy-Induced Neuropathic Pain.
2019,
Pubmed
Wishart,
The chemical shift index: a fast and simple method for the assignment of protein secondary structure through NMR spectroscopy.
1992,
Pubmed
Zakrzewicz,
Canonical and Novel Non-Canonical Cholinergic Agonists Inhibit ATP-Induced Release of Monocytic Interleukin-1β via Different Combinations of Nicotinic Acetylcholine Receptor Subunits α7, α9 and α10.
2017,
Pubmed
Zouridakis,
Crystal Structure of the Monomeric Extracellular Domain of α9 Nicotinic Receptor Subunit in Complex With α-Conotoxin RgIA: Molecular Dynamics Insights Into RgIA Binding to α9α10 Nicotinic Receptors.
2019,
Pubmed
